Turning Point Therapeutics

NASDAQ: TPTX

Initial Filing Date: 03/21/19

Launch Date: 04/08/19

Price Range: $16.00 - $18.00

Shares Offered (Pre-Shoe | mm): 7.4

Primary Shares (mm): 7.4

Secondary Shares (mm): 0.0

Amount Offered (@ Midpoint)(mm): $125.0

% Secondary: 0.0%

Shares Outstanding (mm): 27.8

Market Value at Midpoint (mm): $471.9

Offering as % of Market Value:    26.5%

Bookrunners: GS | LEER | WFS

Co-Managers: CANA

Major Holders:   Cormorant Asset Management | LAV Prime | OrbiMed Private Investments | SR One | Foresite Capital Fund | venBio Partners | Robert Adelman | Yishan Li (Co-Founder) | Jingrong Jean Cui (Co-Founder)

Industry: Healthcare

Description: Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

Note: Emerging Growth Company

Launch Link: S-1/A